TOP News

Health & Fit: ImmunoGen ends losing streak as William Blair cites cancer guidance

Breast cancer deaths keep falling, but wide gap for Black women persists

  Breast cancer deaths keep falling, but wide gap for Black women persists The death rate from breast cancer continues to decline, according to a new report Monday from the American Cancer Society. But there's a wide, worrisome gap in Black women's outcomes that remains unchanged. © Rhoda Baer/Wikimedia Commons The death rate from breast cancer keeps falling, but Black women continue to be 40% more likely to die from the disease despite a lower incidence of it. Photo by Rhoda Baer/Wikimedia Commons Breast cancer death rates dropped by 43% from 1989 to 2020, according to the report.

Oncology-focused biotech ImmunoGen (NASDAQ:IMGN) ended a four-day skid on Wednesday after William Blair pointed to guidelines from the National Comprehensive Cancer (NCCN) to support the potential of the company’s recently approved ovarian cancer therapy Elahere.

Amid concerns over the $6K price tag for Elahere ImmunoGen (IMGN) shares fell in November, a day after its FDA approval for certain adults with FRα-high platinum-resistant ovarian cancer.

However, William Blair analyst Andy Hsieh thinks the NCCN guidelines for ovarian cancer treatment will improve its uptake.

“We are encouraged to see Elahere listed as both a preferred monotherapy and a combination regimen with Avastin in some scenarios,” the analyst wrote.

Selma Blair Had To Stop Performing On “Dancing With The Stars.” Here's What People With Chronic Conditions Think About It.

  Selma Blair Had To Stop Performing On “Dancing With The Stars.” Here's What People With Chronic Conditions Think About It. Blair, who has multiple sclerosis, “pushed as far as [she] could” but ultimately had to leave the competition to protect her health, she said. View Entire Post ›In the latest episode, which aired Oct. 17, Blair told dance partner Sasha Farber that she “pushed as far as [she] could,” but scans revealed her body was “definitely taking a hit.

“The latter was a particular surprise to the upside, since it occurred faster than our (and likely the Street’s) expectations,” Hsieh added, referring to a combination therapy involving Elahere and Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) cancer therapy Avastin.

“It is our view that the NCCN listing as a preferred regimen will boost physician uptake of Elahere, given that NCCN continues to be one of the most reliable guidelines among oncologists,” Hsieh said.

Targeting an FDA label expansion, the company has designed a Phase 3 study to evaluate Elahere in combination with Avastin as maintenance therapy in FRα-high recurrent platinum-sensitive disease.

Read: Seeking Alpha contributor Jonathan Faison thinks that ImmunoGen (IMGN) “has a first-mover opportunity with Elahere in an indication (platinum-resistant ovarian cancer) of high unmet need.”

Now read: Stocks To Watch: Nio, Tesla And Hopes For A Santa Clause Rally

Subscribe to Seeking Alpha here!

Blair Waldorf Style Outift .
This Blair Waldorf-style outfit was created entirely by accident! Don’t you just love when that happens?? I really wanted to style my silk tank since I think the last time I shot it was back in February 2020 in LA. Pre-covid times!! And such a long time ago. And then I wanted to re-style the […] This Blair Waldorf-style outfit was created entirely by accident! Don’t you just love when that happens?? I really wanted to style my silk tank since I think the last time I shot it was back in February 2020 in LA. Pre-covid times!! And such a long time ago. And then I wanted to re-style the tie-waist shorts that I wore in New Orleans in May.

See also